ALD-52

Severe or unstable cardiovascular disease. LSD/ALD-52 produces sympathomimetic stimulation that may pose risk to individuals with pre-existing cardiac conditions, though the cardiovascular effects are modest in healthy populations.

Concurrent lithium use. Case reports associate lithium + psychedelic combinations with seizures. The mechanism is not fully characterized but involves adverse interaction between lithium's neuromodulatory effects and psychedelic-induced cortical excitation.

Epilepsy or history of seizure disorders. Theoretical risk based on 5-HT2A-mediated cortical excitation. Clinical significance at standard doses is uncertain.

Personal or family history of schizophrenia, schizoaffective disorder, or other primary psychotic disorders. Serotonergic psychedelics can trigger acute psychosis or unmask latent vulnerability.

Bipolar disorder, especially with psychotic features. Risk of triggering manic episodes or psychotic decompensation.

Pregnancy. No ALD-52 or LSD teratogenicity data are sufficient to establish safety. Contraindicated by precautionary principle.

Concurrent use of tramadol. The combination creates risk of serotonin syndrome (clonus, hyperreflexia, hyperthermia, agitation) which is life-threatening in severe cases.

Concurrent use of monoamine oxidase inhibitors. Dangerous potentiation of serotonergic effects with risk of serotonin syndrome.